Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.21 CAD | -8.70% | -4.55% | 0.00% |
04-08 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
03-28 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
Valuation
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 71.97 | 62.29 | 71.78 | 117.1 | 32.64 | 42 |
Enterprise Value (EV) 1 | 71.6 | 62.08 | 67.71 | 117.2 | 31.86 | 41.2 |
P/E ratio | -7.78 x | -7.94 x | -7.68 x | -14.2 x | -4.33 x | -6.45 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -8.54 x | -8.43 x | -7.91 x | -12.9 x | -5.28 x | -6.53 x |
EV / FCF | -16.4 x | -22.8 x | -9.49 x | -24.4 x | -7.51 x | -18.7 x |
FCF Yield | -6.11% | -4.39% | -10.5% | -4.1% | -13.3% | -5.35% |
Price to Book | -47.1 x | -19 x | 30 x | -84.1 x | 102 x | -49.8 x |
Nbr of stocks (in thousands) | 102,810 | 111,226 | 132,933 | 141,133 | 171,795 | 200,019 |
Reference price 2 | 0.7000 | 0.5600 | 0.5400 | 0.8300 | 0.1900 | 0.2100 |
Announcement Date | 10/26/18 | 10/25/19 | 10/29/20 | 12/9/21 | 10/31/22 | 10/27/23 |
Income Statement Evolution (Annual data)
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -8.381 | -7.367 | -8.56 | -9.072 | -6.028 | -6.313 |
EBIT 1 | -8.546 | -7.492 | -8.616 | -9.131 | -6.04 | -6.326 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -8.625 | -7.526 | -8.561 | -9.574 | -6.563 | -6.29 |
Net income 1 | -8.625 | -7.526 | -8.985 | -8.038 | -6.563 | -6.29 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.0900 | -0.0706 | -0.0704 | -0.0583 | -0.0439 | -0.0326 |
Free Cash Flow 1 | -4.371 | -2.727 | -7.134 | -4.801 | -4.242 | -2.204 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 10/26/18 | 10/25/19 | 10/29/20 | 12/9/21 | 10/31/22 | 10/27/23 |
Balance Sheet Analysis
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 0.05 | - | - |
Net Cash position 1 | 0.37 | 0.21 | 4.08 | - | 0.78 | 0.81 |
Leverage (Debt/EBITDA) | - | - | - | -0.005181 x | - | - |
Free Cash Flow 1 | -4.37 | -2.73 | -7.13 | -4.8 | -4.24 | -2.2 |
ROE (net income / shareholders' equity) | 1,117% | 313% | 5,707% | -1,206% | 1,222% | 2,396% |
ROA (Net income/ Total Assets) | -320% | -449% | -184% | -127% | -96.9% | -166% |
Assets 1 | 2.692 | 1.677 | 4.877 | 6.318 | 6.776 | 3.786 |
Book Value Per Share 2 | -0.0100 | -0.0300 | 0.0200 | -0.0100 | 0 | -0 |
Cash Flow per Share 2 | 0 | 0 | 0.0300 | 0.0300 | 0.0200 | 0 |
Capex 1 | 0.05 | 0 | 0.02 | - | - | 0.01 |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 10/26/18 | 10/25/19 | 10/29/20 | 12/9/21 | 10/31/22 | 10/27/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 38.57M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- HBP Stock
- Financials Helix BioPharma Corp.